Sign In
Section Navigation
Common TitleStudy 106
Official Title A Phase 2/3, Open-Label Study of the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents and Virologically Suppressed Children
Phase Phase IIB
ClinicalTrials.gov NCT01854775
Treatments
Tenofovir alafenamide-Emtricitabine
Tenofovir alafenamide-Emtricitabine Descovy

Tenofovir alafenamide-Emtricitabine

Tradename:DescovyOther Names:TAF-FTCClass:Nucleoside Reverse Transcriptase Inhibitors (NRTI)
Categories PharmacologyPediatricsTreatment-NaiveAdverse Effects
Funding
IndustryGilead Sciences
References
  • Gaur AH, Kizito H, Prasitsueubsai W, et al. Safety, efficacy, and pharmacokinetics of a single-tablet regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in treatment-naive, HIV-infected adolescents: a single-arm, open-label trial. Lancet HIV. 2016;3:e561-e568.
    [PubMed Abstract]

Share by e-mail

Since you've received 80% or better on this quiz, you may claim continuing education credit.

You seem to have a popup blocker enabled. If you want to skip this dialog please Always allow popup windows for the online course.